Low Completion Rate for the 6-months Course of Isoniazid Preventive Therapy Among People Living with HIV, North Eastern Uganda, 2015-2017

Overview

Journal Pan Afr Med J

Date 2024 Nov 11

PMID 39525548

Authors

Daniel Eurien

Denis Okethwangu

Dativa Maria Aliddeki

Esther Kisaakye

Joy Nguna

Lilian Bulage

Shaaban Mugerwa

Alex Riolexus Ario

Affiliations

Soon will be listed here.

Abstract

Introduction: isoniazid preventive therapy (IPT) is highly effective at preventing tuberculosis among Persons Living with HIV (PLHIV). However, IPT completion rates in Uganda have not been studied. We examined completion rates for the 6-month course of IPT and factors associated with non-completion among PLHIV in northeastern Uganda.

Methods: we conducted a retrospective cohort study using routinely collected program data in nine Antiretroviral Therapy (ART) sites in northeastern Uganda. The study period covered January 20 5-December 20 7. Non-completion was defined as failure to pick up any of the six IPT refills over 6 months. We abstracted data on IPT treatment site, IPT completion, and demographic and clinical characteristics from the IPT register and patient HIV care card. We used generalized linear regression to identify factors associated with non-completion.

Results: among 543 patients who started IPT, 175 (32%) completed the full 6-month course. Among those who did not complete, 193 (52%) stopped due to drug stockouts, and 175 (48%) were lost to follow-up. Being at World Health Organization (WHO) HIV clinical stages III and IV at initiation were associated with a higher risk of IPT non-completion compared to those who were at WHO clinical staging I and II (aRR 1.4, 95%CI 1.2-1.5).

Conclusion: IPT completion rate among PLHIV in northeastern Uganda was suboptimal, largely due to IPT drug stockouts. The National TB and Leprosy Program should streamline the IPT supply chain to address drug stockouts and improve completion rates.

References

Ayele H, van Mourik M, Bonten M . Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. Int J Tuberc Lung Dis. 2016; 20(10):1342-1347. DOI: 10.5588/ijtld.15.0805. View

Shayo G, Moshiro C, Aboud S, Bakari M, Mugusi F . Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania. BMC Infect Dis. 2015; 15:368. PMC: 4549887. DOI: 10.1186/s12879-015-1085-7. View

Kagujje M, Mubiana M, Mwamba E, Muyoyeta M . Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health. 2019; 19(1):1329. PMC: 6805296. DOI: 10.1186/s12889-019-7652-x. View

Golub J, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H . Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009; 23(5):631-6. PMC: 3063949. DOI: 10.1097/QAD.0b013e328327964f. View

Adams L, Mahlalela N, Talbot E, Pasipamire M, Ginindza S, Calnan M . High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland. Int J Tuberc Lung Dis. 2017; 21(10):1127-1132. DOI: 10.5588/ijtld.16.0946. View

Hwang B, Shroufi A, Gils T, Steele S, Grimsrud A, Boulle A . Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey. PLoS One. 2019; 14(3):e0212405. PMC: 6413937. DOI: 10.1371/journal.pone.0212405. View

Gupta A, Wood R, Kaplan R, Bekker L, Lawn S . Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012; 7(3):e34156. PMC: 3316623. DOI: 10.1371/journal.pone.0034156. View

Masini E, Sitienei J, Weyeinga H . Outcomes of isoniazid prophylaxis among HIV-infected children attending routine HIV care in Kenya. Public Health Action. 2015; 3(3):204-8. PMC: 4463120. DOI: 10.5588/pha.13.0013. View

Yirdaw K, Jerene D, Gashu Z, Edginton M, Kumar A, Letamo Y . Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014; 9(8):e104557. PMC: 4126726. DOI: 10.1371/journal.pone.0104557. View

10.

Namuwenge P, Mukonzo J, Kiwanuka N, Wanyenze R, Byaruhanga R, Bissell K . Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg. 2011; 106(2):84-9. DOI: 10.1016/j.trstmh.2011.10.015. View

11.

Kwan C, Ernst J . HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011; 24(2):351-76. PMC: 3122491. DOI: 10.1128/CMR.00042-10. View

12.

Nabukeera-Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke E . Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis. 2015; 15:520. PMC: 4647509. DOI: 10.1186/s12879-015-1265-5. View

13.

Harries A, Schwoebel V, Monedero-Recuero I, Aung T, Chadha S, Chiang C . Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries. Int J Tuberc Lung Dis. 2019; 23(2):241-251. DOI: 10.5588/ijtld.18.0207. View

14.

Ousley J, Niyibizi A, Wanjala S, Vandenbulcke A, Kirubi B, Omwoyo W . High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites. Clin Infect Dis. 2018; 66(suppl_2):S126-S131. PMC: 5850537. DOI: 10.1093/cid/ciy103. View

15.

Tram K, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A . Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr. 2017; 76(5):e115-e117. PMC: 5680115. DOI: 10.1097/QAI.0000000000001540. View

16.

Yotebieng M, Edmonds A, Lelo P, Wenzi L, Ndjibu P, Lusiama J . High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. AIDS. 2015; 29(15):2055-7. PMC: 4566165. DOI: 10.1097/QAD.0000000000000791. View

17.

Tram K, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J . Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care. 2019; 32(1):119-127. PMC: 6883160. DOI: 10.1080/09540121.2019.1619661. View

18.

Blankley S, Gashu T, Ahmad B, Belaye A, Ringtho L, Mesic A . Lessons learned: Retrospective assessment of outcomes and management of patients with advanced HIV disease in a semi-urban polyclinic in Epworth, Zimbabwe. PLoS One. 2019; 14(4):e0214739. PMC: 6457534. DOI: 10.1371/journal.pone.0214739. View

19.

Mfinanga S, Chanda D, Kivuyo S, Guinness L, Bottomley C, Simms V . Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015; 385(9983):2173-82. DOI: 10.1016/S0140-6736(15)60164-7. View